Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

nervous
chemotherapeutic agents
graft versus host disease
brain stem tumors
brain stem tumor
  • 1032 views
  • 19 Sep, 2022
  • 107 locations
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer

cancer
solid tumor
lung cancer
advanced malignant solid tumor
measurable disease
  • 14 views
  • 27 Jan, 2022
  • 1 location
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

This double-blind, randomized, placebo-controlled, multicenter, Phase III study is designed to evaluate the efficacy and safety of ensatinib compared with placebo as adjuvant treatment in ALK positive stage II-IIIB non-small cell lung cancer after surgical resection with or without chemotherapy.

non-small cell carcinoma
lung carcinoma
carcinoma
neutrophil count
cancer chemotherapy
  • 0 views
  • 25 Jul, 2022
  • 1 location
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

This is a Phase II, single-Arm, prospective study of neoadjuvant Ensartinib for the treatment of patients with ALK positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer

  • 0 views
  • 19 Aug, 2022
  • 1 location
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations

chemotherapeutic agents
solid tumor
graft versus host disease
nitrosourea
measurable disease
  • 68 views
  • 17 Sep, 2022
  • 72 locations
A Real World Study of Ensartinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

The primary objective of this study is to evaluate the efficacy and safety of Ensartinib in advanced ALK-positive non-small cell lung cancer, and the mechanisms of population pharmacokinetics

  • 0 views
  • 19 Aug, 2022